Sprache auswählen
GUCY2C
GUCY2C Molekülinformation
| Englischer Name | Heat-stable enterotoxin receptor | Anzahl der inverkehr gebrachten Arzneimittel | 1 |
| Anzahl der klinischen Arzneimittel | 9 | Target-Alias | GUC2C，Intestinal guanylate cyclase，hSTAR，EC:4.6.1.2，EC 4.6.1，GC-C，GUCY2C，Guanylate Cyclase 2C，STA Receptor，Guanylyl Cyclase C，Guanylate Cyclase 2C (Heat Stable Enterotoxin Receptor)，Heat-Stable Enterotoxin Receptor，STAR，Heat Stable Enterotoxin Receptor，EC 4.6.1.2，DIAR6，MECIL，MUCIL |
| Höchste Forschungs- und Entwicklungsphase | Approved | ||
| Englischer Name | Heat-stable enterotoxin receptor |
| Target-Alias | GUC2C，Intestinal guanylate cyclase，hSTAR，EC:4.6.1.2，EC 4.6.1，GC-C，GUCY2C，Guanylate Cyclase 2C，STA Receptor，Guanylyl Cyclase C，Guanylate Cyclase 2C (Heat Stable Enterotoxin Receptor)，Heat-Stable Enterotoxin Receptor，STAR，Heat Stable Enterotoxin Receptor，EC 4.6.1.2，DIAR6，MECIL，MUCIL |
| Anzahl der inverkehr gebrachten Arzneimittel | 1 |
| Anzahl der klinischen Arzneimittel | 9 |
| Höchste Forschungs- und Entwicklungsphase | Approved |
GUCY2C Produktliste
- Attribut
Protein (21)Cell (1)Antibody (1)
- Produktbibliothek
Online (22)In Forschung (1)
- Spezies
Human (15)Mouse (4)Cynomolgus (3)Rabbit (1)
- Etikett
Fc Tag (4)His Tag (13)Fc Tag & Avi Tag (1)His Tag & Avi Tag (3)- (2)
- Marker
Unconjugated (8)FITC Labeled (3)Biotin-labeled (4)PE Labeled (2)AF488 Labeled (1)APC Labeled (2)AF647 Labeled (1)AF555 Labeled (1)- (1)
In den Warenkorb legen
Gesamtmenge23
- 1
- 2
- 3
GUCY2C Molekülhintergrund
GUCY2C (Guanylyl Cyclase C), also known as heat-stable enterotoxin receptor, is a type I transmembrane protein of the guanylate cyclase (gc) family that signal by producing cGMP. Guanylate cyclase C (GUCY2C) and its hormones guanylin and uroguanylin have recently emerged as one paracrine axis defending intestinal mucosal integrity against mutational, chemical, and inflammatory injury. GUCY2C murine CAR-T cells recognized and killed human colorectal cancer cells endogenously expressing GUCY2C. Thus, we have identified a human GUCY2C-specific CAR-T cell therapy approach that may be developed for the treatment of GUCY2C-expressing metastatic colorectal cancer.
GUCY2C Molekülalias
GUCY2C,GUC2C,STAR,STA receptor,hSTAR,GC-C
Lizenzierungszusammenarbeit
| Projektname | Arzneimitteltyp | Therapiegebiet | Indikationen | Stufe | Rechtsgebiet |
|---|---|---|---|---|---|
| Anti-GCC humanized antibody | Bispecific antibody | Oncology/Cancer | Solid Tumor | Preclinical | Global |
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| anti-GUCY2C CAR T-cell therapy (Parasol Biotechnology/Anhui provincial cancer hospital) | Phase 1 Clinical | HeFei Parasol Biotech Co Ltd | Colorectal Neoplasms | Details | |
| anti-guanylyl cyclase C CAR-T cell therapy (Legend Biotech) | LCAR-G08T | Phase 1 Clinical | Legend Biotech Corp | Colorectal Neoplasms; Gastrointestinal Neoplasms | Details |
| HD-006 | HD006; HD-006 | Phase 1 Clinical | Huadao (Shanghai) Biopharma Co Ltd | Solid tumours | Details |
| REVO-UWD-01 | REVO-UWD-01; WD 01 | Phase 1 Clinical | Wondercel Therapeutics Co Ltd | Colorectal Neoplasms | Details |
| IM96 CAR-T cell Therapy | IM96 | Phase 1 Clinical | Imunopharm Technology Co Ltd | Colorectal Neoplasms; Digestive System Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| GCC19CART | GCC19CART; LYL273; LYL-273 | Phase 1 Clinical | Innovative Cellular Therapeutics Co Ltd | Colorectal Neoplasms; Rectal Neoplasms | Details |
| Gucy2c cart cell therapy (Innovative Cellular Therapeutics) | Phase 1 Clinical | Innovative Cellular Therapeutics Co Ltd | Digestive System Neoplasms | Details | |
| XKDCT-080 | XKDCT-080 | Clinical | The Affiliated Hospital Of Qingdao University | Colonic Neoplasms; Solid tumours | Details |
| CT-080 | CT-080 | Clinical | Shenzhen Celconta Life Science Co Ltd | Solid tumours | Details |
Inverkehr gebrachte Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Plecanatide | SP-304; GCRA | Approved | Synergy Pharmaceuticals Inc | Trulance | United States | Constipation; Chronic idiopathic constipation | Salix Pharmaceuticals | 2017-01-19 | Chronic idiopathic constipation; Constipation; Irritable Bowel Syndrome | Details |
- Molekülinformation
- Produktliste
- Inverkehr gebrachte Arzneimittelinformation
- Klinische Arzneimittelinformation
Teilen auf:
Online-Nachricht
Kontaktieren Sie uns
BettinastraBe 30, 60325 Frankfurt am Main